-
Decoding Tenax Therapeutics’ Latest Update: What the Blinded Sample Size Assessment Really Means
NASDAQ: $TENX Unpacking the Latest News from Tenax Therapeutics The world of clinical trials is often shrouded in complexity, full of acronyms and technical jargon that can leave even seasoned investors scratching their heads. Recently, a press release from Tenax Therapeutics ($TENX) caught the attention of the biotech community, specifically concerning the results of a…
-
Decoding the Future of Rare Disease Treatment: Travere Therapeutics at J.P. Morgan Healthcare Conference 2026
NASDAQ: $TVTX The Annual Gathering of Titans: Why J.P. Morgan Matters Every January, the city of San Francisco transforms into the epicenter of the global life sciences industry. The J.P. Morgan Healthcare Conference (JPM) is more than just a series of presentations; it’s where deals are forged, strategies are unveiled, and the trajectory of pharmaceutical…
-
Sanofi’s $2.2 Billion Bet: What Their Acquisition of an HBV Vaccine Maker Means for Global Health
NASDAQ: $SNY In a move that sent ripples through the pharmaceutical landscape, Sanofi recently announced its acquisition of a Hepatitis B (HBV) vaccine maker for a staggering $2.2 billion. This strategic purchase, detailed in a recent article from Pharmaceutical Technology, isn’t just a financial transaction; it represents a significant investment in global public health and…
-
NRx Pharmaceuticals Achieves Debt-Free Status Ahead of Drug Approvals
NASDAQ: $NRXP Summary of the Article/Press Release On December 18, 2025, NRx Pharmaceuticals, Inc. (Nasdaq: $NRXP), a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders like suicidal depression and PTSD, announced that it has fully eliminated its balance sheet debt. CEO Dr. Jonathan Javitt thanked Anson Funds for their support during tough…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF SEPTEMBER 28, 2025 – OCTOBER 04, 2025
September 28, 2025 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Clinical Trial 09/30/2025 AGEN 53.89 6,179 0.00 Clinical Trial 09/30/2025 BTAI 53.32 4,080 0.00 PDUFA 09/30/2025 FBIO 28.17 1,996 0.00 Clinical Trial 09/30/2025 ALEC 25.87 730 0.00 Clinical Trial 09/30/2025 STRO 44.79 170 0.00 Clinical Trial 09/30/2025 RCKT 34.65 2,506…
-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
NASDAQ: $SRPT Sarepta Therapeutics (NasdaqGS: $SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF FEBRUARY 2, 2025 – FEBRUARY 08, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Data Release 02/03/2025 IVVD 55.1 44 0.36 Conference 02/05/2025 ANAB 30.6 2,770 17.93 Conference 02/05/2025 CABA 22.5 12,509 2.39 Conference 02/05/2025 ABSI 23.2 14,305 3.71 Conference 02/06/2025 PRAX 33.6 13,932 76.55 Conference 02/06/2025 FBRX 23.4 504 15.89 Conference 02/06/2025 ADCT 32.3 172 1.68…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF JANUARY 26, 2025 – FEBRUARY 01, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Conference 01/28/2025 LXRX 49.9 4,606 0.99 Conference 01/28/2025 IPA 28.7 3,588 0.58 Webinar 01/29/2025 OTLK 21.0 1,839 1.99 Corporate Event 01/29/2025 ZNTL 58.3 4,312 2.22 FDA Event 01/30/2025 VRTX 17.34 48,375 439.62 FDA Event 01/31/2025 AXSM 13.99 45,376 103.11 Clinical Trial 02/01/2025 SUPN…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 29, 2024 – JANUARY 04, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ FDA Event 12/29/2024 NBIX 4.2 1,817 139.44 FDA Event 12/29/2024 BMY 2.5 5,932 57.68 Clinical Trial 12/30/2024 BCLI 42.3 782 2.45 FDA Event 12/30/2024 NBIX 4.2 1,817 139.44 Clinical Trial 12/31/2024 ALDX 13.0 6,889 4.94 Clinical Trial 12/31/2024 ABBV 2.1 6,221 178.01 Clinical…
-
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
NASDAQ: $CLOV Clover Health’s upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference holds significant promise for the healthcare industry and market observers alike. As a key player in the healthcare sector, Clover Health’s involvement in this prestigious event underscores its commitment to innovation, growth, and industry leadership. This article delves into the details…